Summary of Significant Accounting Policies (Tables)

9 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of Accounts Receivable

	As of
	December 31, 2024		March 31, 2024
Accounts Receivable	$	164,221	$	235,423

Schedule of Equity Investments

	As of December 31, 2024
Cost Basis	$	1,298,050
Unrealized gain/(loss)		(197,277	)
Equity securities - Fair value	$	1,100,773

Schedule of Disaggregated Revenue

The Company’s disaggregated revenue by category is as follows:

	For the nine months ended December 31,
	2024		2023
Core:
Sale of Pharmaceutical products – RxCompound and Peaks	$	23,916,541	$	5,937,766
Total core revenue, net	$	23,916,541	$	5,937,766
Non-Core:
Shipping income		524,059		-
Total revenue, net	$	24,440,600	$	5,937,766